LVAD DT denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for lvad dt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies LVAD Destination Therapy as Experimental

Aetna may classify a treatment as "experimental or investigational" when it determines the evidence base does not meet its coverage criteria for established medical practice. For LVAD destination therapy, this denial is increasingly rare given its FDA-approved status and long clinical track record in advanced heart failure — but it does still occur, typically when the specific device model is newer, the indication is at the edges of approved labeling, or Aetna's Clinical Policy Bulletin has not yet been updated to reflect evolving evidence. Check Aetna's current Clinical Policy Bulletin for LVAD-DT to identify exactly which criterion was not met.

## Why This Denial Is Appealable

Experimental/investigational denials for FDA-approved devices are among the most strongly appealable denial types. FDA approval itself is significant evidence that a device is not investigational. Additionally, ACA §2719 mandates external review by an accredited Independent Review Organization for these denials — specifically, the IRO must apply generally accepted standards of medical practice, not the insurer's internal policy. File an internal appeal within the deadline on the denial notice. Request external IRO review within approximately four months of exhausting internal remedies. Given the life-sustaining nature of LVAD-DT, request expedited (72-hour) review.

## The Concrete Appeal Process

1. Obtain Aetna's Clinical Policy Bulletin for LVAD/mechanical circulatory support — identify the exact criterion that resulted in the experimental classification. 2. Confirm FDA approval status of the specific device model and indication — attach the FDA approval letter or 510(k)/PMA summary. 3. File an internal appeal with FDA documentation, cardiology team support letter, and guideline references. 4. Request external IRO review — note that for experimental/investigational denials under ACA §2719, the IRO applies objective clinical standards, which strongly favors FDA-approved therapies.

## Documentation to Gather

• FDA approval documentation: the FDA-approved labeling and clearance documentation for the specific LVAD device and the destination-therapy indication.
• Cardiology specialist letter: a letter from the treating heart failure cardiologist or cardiac surgeon explaining the established clinical evidence base for LVAD-DT, referencing the applicable cardiovascular guideline organization (such as ACC/AHA) by name without fabricating statistics.
• Advanced heart failure diagnosis documentation: chart notes confirming disease stage, transplant ineligibility, and the patient's clinical profile relative to the approved indication in the FDA label.
• Aetna's experimental criteria: a copy of Aetna's Clinical Policy Bulletin showing the specific experimental/investigational criteria and a point-by-point response.
• Professional society guideline citation: note the guideline organization that includes LVAD-DT as a recognized treatment option — the prescriber's letter should reference this.

## Criteria-Mapping Structure

For an experimental denial of an FDA-approved device, the appeal structure is: (1) FDA approval documentation proving the device and indication are not investigational; (2) applicable guideline organization endorsement referenced in the physician letter; (3) point-by-point response to each criterion in Aetna's Clinical Policy Bulletin that triggered the experimental classification; (4) request for expedited external IRO review with explicit citation of the ACA §2719 right to IRO review for experimental/investigational denials. This is one of the strongest appeal postures available.